Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials

Author(s):  Mueller Claudia, Dietel Elde, Heynen Severin R, Nalenz Heiko, Goldbach Pierre, Mahler Hanns-Christian, Schmidt Johannes, Grauschopf Ulla, Schoenhammer Karin

Issue:  May/Jun 2015 - Volume 19, Number 3
View All Articles in Issue

Page(s):  261-267

Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 1
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 2
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 3
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 4
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 5
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 6
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials Page 7

Download in electronic PDF format for $75

Abstract:  MabThera is an essential component of the standard-of–care regimens in the treatment of non-Hodgkin lymphoma and Chronic Lymphatic Leukemia. MabThera for subcutaneous injection is a novel line extension that has been approved by the European Medicines Agency for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. This study aimed to evaluate in-use stability data of MabThera subcutaneous drug-product solution in single-use syringes for subcutaneous administration according to the European Medicines Agency guideline. The drug-product solution was exposed to material contact surfaces of five different administration setups commonly used in subcutaneous drug delivery. MabThera subcutaneous was transferred under aseptic conditions into polypropylene and polycarbonate syringes and stored for 1, 2, and 4 weeks at 2°C to 8°C followed by 24 hours at 30°C. After storage, subcutaneous administration was simulated and MabThera subcutaneous drug-product solution quality attributes were evaluated by using compendial physico-chemical tests, as well as suitable and validated molecule- and formulation-specific analytical methods. MabThera subcutaneous vials were treated and analyzed in parallel. The physicochemical results of MabThera subcutaneous in the different setups were comparable to the control for all timepoints. No change in drug-product quality after storage and simulated administration was found compared to the control. However, since single-dose products do not contain preservatives, microbial contamination and growth needs to be avoided and product sterility needs to be ensured. The results showed that MabThera subcutaneous remains compatible and stable, from a physico-chemical perspective, for up to 4 weeks at 2°C to 8°C followed by 24 hours at 30°C with the contact materials tested in this study. In order to avoid and minimize microbial growth, MabThera subcutaneous should be used immediately after removal from the original packaging container and strict aseptic handling conditions need to be followed.

Related Keywords: Claudia Mueller, PhD, Elke Dietel, PhD, Severin R. Heynen, PhD, Heiko Nalenz, PhD, Pierre Goldbach, PhD, Hanns-Christian Mahler, PhD, PD, Johannes Schmidt, PhD, Ulla Grauschopf, PhD, Karin Schoenhammer, PhD, MabThera drug product solution, rituximab, CD20, lymphoma, B-cell leukemia, autoimmune disorders, intravenous immunoglobulin, subcutaneous administration, hyaluronidase, stability

Related Categories: CANCER AND AIDS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, STERILE PREPARATIONS, ALLERGY/IMMUNOLOGY/INFLAMMATION

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials
Mueller Claudia
, Dietel Elde, Heynen Severin R, Nalenz Heiko, Goldbach Pierre, Mahler Hanns-Christian, Schmidt Johannes, Grauschopf Ulla, Schoenhammer Karin
May/Jun 2015
Pg. 261-267

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags
Nalenz Heiko
, Köpf Ellen, Dietel Elke
Sep/Oct 2018
Pg. 417-423

Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
May/Jun 2003
Pg. 170-174

Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients
Allen Loyd V Jr
Nov/Dec 2023
Pg. 474-481

The Value of Near Infrared Spectroscopy in a Small Hospital Compounding Unit to Control the Risks Associated with Raw Materials
Storme-Paris Isabelle
, Storme Thomas, Thauvin Maxime, Brion Francoise, Chaminade Pierre, Rieutord Andre
Jan/Feb 2009
Pg. 81-86

Use of a Closed-system Drug Transfer Device (PhaSeal) and Impact on Preparation Time
Sanchez-Rubio Ferrandez J
, Lozano M C, Iglesias I, Sanchez-Rubio Ferrandez L, Rodriguez Vargas B, Moreno Diaz R
Sep/Oct 2012
Pg. 431-433

Extemporaneous Topical Minoxidil Solutions for the Treatment of Alopecia: Stability Studies and Incorporation Tests of Active Ingredients in ALOPLUS FAST Base
Spennacchio Antonio
, Lopedota Angela Assunta, Lopalco Antonio, Dibenedetto Maria Teresa, la Forgia Flavia Maria, Fontana Sergio, Franco Massimo, Denora Nunzio
May/Jun 2023
Pg. 256-262

Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design
Patel Gopesh
, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
Jan/Feb 2021
Pg. 73-81

Stability Studies of Fludrocortisone Acetate Capsules and Fludrocortisone Acetate Titrated Powders (Powder Triturates)
Brandin Thibaut
, Wasilewski Maya, Panuccio Camille, Bouguergour Cyrielle, Primas Nicolas, Lamy Edouard, Jean Christophe, Bertault-Peres Pierre, Rathelot Pascal, Curti Christophe, Vanelle Patrice
Mar/Apr 2022
Pg. 150-154

Compounding and Characterization of Oral Disintegrating Films Containing Memantine Hydrochloride for Geriatrics
Rofiq Hanifah Mohd
, Phang Hiu Ching, Janakiraman Ashok Kumar, Chew Yik-Ling, Uddin ABM Helal, Sarker Zaidul Islam, Lee Siew-Keah, Liew Kai Bin
Nov/Dec 2023
Pg. 512-521

Long-term Stability of Vancomycin Hydrochloride in Oral Solution: The Brand Name Versus a Generic Product
Huvelle Sophie
, Godet Marie, Hecq Jean-Daniel, Gillet Patricia, Jamart Jacques, Galanti Laurence M
Jul/Aug 2016
Pg. 347-350

Stability of Omeprazole Extemporaneous Oral Solution in Chopin Base
Spennacchio Antonio
, Lopedota Angela Assunta, la Forgia Flavia Maria, Fontana Sergio, Denora Nunzio, Lopalco Antonio
May/Jun 2023
Pg. 250-255

Compounded Orodispersible Films with Natural Ingredients for Halitosis: A Clinical Experience
Apolinário Régis De Souza
, Chaves Maria Das Graças Afonso Miranda, Gonçalves Hanny Reis Mockdeci, Martins Isadora Conde Ferreria, De Paula Renée Mazilão, Granato Ana Paula Alves, Polonini Hudson Caetano, Brandão Marcos Antônio Fernandes, Ferreira Anderson De Oliveira, Raposo Nádia Rezende Barbosa
Nov/Dec 2018
Pg. 512-515

Physicochemical Stability of Compounded Naltrexone Hydrochloride Solutions in PCCA Base SuspendIt
Pramar Yashoda V
, Mandal Tarun K, Bostanian Levon A, Nguyen Anh TQ, Morris Tommy C, Graves Richard A
Mar/Apr 2019
Pg. 157-162

Study of Microbiological Safety of 25 Oncology Drugs After Multiple Uses in Aseptic Conditions
Roy Julie
, Brault Julie, Joran Pierre, Metrop Raphael, Hildgen Patrice
Sep/Oct 2011
Pg. 428-434

Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine
Catry Emilie
, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence
May/Jun 2022
Pg. 248-254

Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base
Spennacchio Antonio
, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Jan/Feb 2023
Pg. 72-77

Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V
, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Sep/Oct 2021
Pg. 431-439

Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Nov/Dec 2018
Pg. 516-526

Return to Top